Nature Reviews Urology




One-year access to more than 500 world journals available in the system
    http://medilib.ir
  • Duration of Time : 365 Day
  • Price : 300$
  • Special Price : 100$
Order

Can PROMs improve racial equity in outcomes after prostatectomy?

Alexander P. Cole, Mara Koelker, Jonathan Makanjuola & Caroline M. MooreÂ

doi : 10.1038/s41585-022-00682-2

Volume 20 Issue 3, March 2023

Buy The Package and View The Article Online


Partial gland cryoablation for prostate cancer � where are we?

Wei Phin Tan, James S. Wysock & Herbert LeporÂ

doi : 10.1038/s41585-022-00685-z

Buy The Package and View The Article Online


GAH treatment improves mental health in transgender adolescents

Maria Chiara Masone 

doi : 10.1038/s41585-023-00728-z

Buy The Package and View The Article Online


CMA mediates resistance to androgen inhibitors in prostate cancer

Maria Chiara Masone 

doi : 10.1038/s41585-023-00729-y

Buy The Package and View The Article Online


A new text message-based platform for self-management of patients with IC/BPS

Maria Chiara Masone 

doi : 10.1038/s41585-023-00730-5

Buy The Package and View The Article Online


Prostate cancer care for American Indians and Alaska Natives

Maria Chiara Masone 

doi : 10.1038/s41585-023-00731-4

Buy The Package and View The Article Online


Calculating the environmental cost of care

Louise Stone 

doi : 10.1038/s41585-023-00733-2

Buy The Package and View The Article Online


Metabolic flexibility in ccRCC

Louise Stone 

doi : 10.1038/s41585-023-00734-1

Buy The Package and View The Article Online


PARP inhibitor response in prostate cancer

Louise Stone 

doi : 10.1038/s41585-023-00735-0

Buy The Package and View The Article Online


An epigenomic atlas for RCC

Louise Stone 

doi : 10.1038/s41585-023-00736-z

Buy The Package and View The Article Online


Immunoproteasome inhibition in CRPC

Louise Stone 

doi : 10.1038/s41585-023-00737-y

Buy The Package and View The Article Online


GHR expression and prostate cancer proliferation

Tim Thomas 

doi : 10.1038/s41585-023-00740-3

Buy The Package and View The Article Online


Semen parameters across testicular cancer stages

Tim Thomas 

doi : 10.1038/s41585-023-00741-2

Buy The Package and View The Article Online


Semen quality recovery following COVID-19

Tim Thomas 

doi : 10.1038/s41585-023-00742-1

Buy The Package and View The Article Online


Pembrolizumab + axitinib beyond first-line therapy for mRCC

Tim Thomas 

doi : 10.1038/s41585-023-00743-0

Buy The Package and View The Article Online


Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

Matteo Rosellini, Andrea Marchetti, Veronica Mollica, Alessandro Rizzo, Matteo Santoni & Francesco MassariÂ

doi : 10.1038/s41585-022-00676-0

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of immunotherapy agents by regulatory agencies. However, objective and durable responses are still not observed in a large number of patients, and prognostic and predictive biomarkers for immunotherapy response are urgently needed.

Buy The Package and View The Article Online


Experimental in vitro, ex vivo and in vivo models in prostate cancer research

Verena Sailer, Gunhild von Amsberg, Stefan Duensing, Jutta Kirfel, Verena Lieb, Eric Metzger, Anne Offermann, Klaus Pantel, Roland Schuele, Helge Taubert, Sven Wach, Sven Perner, Stefan Werner & Achim AignerÂ

doi : 10.1038/s41585-022-00677-z

Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression.

Buy The Package and View The Article Online


Adjuvant therapy options in renal cell carcinoma � targeting the metastatic cascade

Kelly N. Fitzgerald, Robert J. Motzer & Chung-Han LeeÂ

doi : 10.1038/s41585-022-00666-2

Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is performed with curative intent. However, disease recurs in ~20% of patients. Treatment with adjuvant therapies is used after surgery with the intention of curing additional patients by disrupting the establishment, maturation or survival of micrometastases, processes collectively referred to as the metastatic cascade.

Buy The Package and View The Article Online


Author Correction: Can PROMs improve racial equity in outcomes after prostatectomy?

Alexander P. Cole, Mara Koelker, Jonathan Makanjuola & Caroline M. MooreÂ

doi : 10.1038/s41585-022-00712-z

Buy The Package and View The Article Online


Do you want to add Medilib to your home screen?